The bicalutamide Early Prostate Cancer Program. Demography

W A. See, D McLeod, P Iversen, M Wirth

    71 Citationer (Scopus)


    BACKGROUND: The optimal treatment for early prostate cancer has yet to be established. A well-tolerated hormonal therapy such as bicalutamide could be a useful treatment option in this setting, either as adjuvant or immediate therapy. A major collaborative clinical trials program was set up to investigate bicalutamide as a treatment option for local prostate cancer (localized or locally advanced disease). METHODS: The bicalutamide Early Prostate Cancer program comprises three randomized, double-blind, placebo-controlled trials of similar design that are being conducted in distinct geographical areas (North America; Australia, Europe, Israel, South Africa and Mexico; and Scandinavia). Men with T1b-4N0-1M0 (TNM 1997) prostate cancer have been randomized on a 1:1 basis to receive bicalutamide 150 mg daily or placebo. Recruitment to the program closed in July 1998, and follow-up is ongoing. Study endpoints include time to clinical progression, overall survival and tolerability. RESULTS: 8113 men aged 38 to 93 years (mean 66.9) were randomized over a 3-year period. 67.4% of the enrolled patients had localized disease (T1-2) and 66.4% had a Gleason score
    TidsskriftUrologic Oncology
    Udgave nummer2
    Sider (fra-til)43-47
    Antal sider5
    StatusUdgivet - 2001


    Dyk ned i forskningsemnerne om 'The bicalutamide Early Prostate Cancer Program. Demography'. Sammen danner de et unikt fingeraftryk.